INTRODUCTION AND OBJECTIVES: Renal medullary carcinoma (RMC) is a rare renal neoplasm accounting for less than 1% of all renal cell carcinomas. RMC, which frequently occurs in young African Americans with sickle cell trait, is an aggressive and lethal cancer with a median overall survival of about 13 months. Recent studies identified the biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex, as a characteristic feature of RMC tumors. Other reports suggest that the presence of vinculin-anaplastic lymphoma kinase (VCL-ALK) fusion without SMARCB1 loss may represent an RMC variant. We hypothesize that in addition to these alterations, novel driver mutations are present and may become potential targets for treatment. To test this hypothesis, we carried out whole exome sequencing of RMC tumor specimens.
INTRODUCTION AND OBJECTIVES: Large molecular and genomic studies have shown that clear-cell renal cell carcinomas (RCC) share common genomic alterations such as loss of chromosome 3p and VHL gene mutations. However, some clear-cell RCCs do not show these alterations and instead have hotspot mutations in the ELOC gene (aka. TCEB1 -Ch8q21.11). The ELOC gene product is known to bind to the VHL-complex and aid in the ubiquitination/degradation of hypoxiainducible factor-1a. Hotspot mutations in ELOC seem to lead to a 'VHLlike' tumor development mechanism. Previous reports have hypothesized that these tumors may have a more indolent course, however, adequate follow-up was lacking.
METHODS: We performed next-generation sequencing of 468 cancer-associated genes on kidney tumor samples from 524 patients (MSK-IMPACT gene panel, mean coverage¼500x). Patients with ELOC mutations were identified and their medical records were reviewed. Two experienced genitourinary pathologists performed pathological review and immunohistochemical staining of the samples. Clinical and pathological variables, copy number alterations and mutation profiles were analyzed.
RESULTS: Sequencing analysis identified a total of 4 tumors with ELOC mutations. All of them had hotspot mutations Y79C (figure 1) and were VHL and PBRM1 wild type (figure 2). Copy number analysis demonstrated loss of heterozygosity on chromosome 8, and absence of the signature 3p loss. During the follow-up period (median 50.3 months), 1 patient died (6.6%) and 2 developed metastasis (13.3%). The deceased patient also had a TP53 (R248W) hotspot mutation and a SETD2 splice-site mutation (X2477).
CONCLUSIONS: ELOC-mutated RCC seems to be a distinct entity with specific genomic and morphological alterations. Previous reports suggested that these tumors might be more indolent, however, longer clinical follow-up was needed to assess their aggressiveness. We provide evidence that some of these patients present with more aggressive disease. Inter-and intra-tumor molecular heterogeneity is increasingly recognized in clear cell renal cell carcinoma (ccRCC). It could, in part, explain the diversity of responses to targeted therapies and the varied clinical outcomes observed for histologically similar tumors. The present study aimed to examine intra-tumor molecular heterogeneity in primary and metastatic ccRCC tissues and their responses to targeted therapies.
METHODS: A ccRCC patient with multiple metastases received radical nephrectomy and resection of the metastatic tumor in chest wall. Meanwhile, the specimens were implanted into immunedeficient mice to establish Patient-Derived Xenografts (PDXs), with KI2367 derived from primary tumor and KI2368 from metastasis. KI2367 and KI2368 was transcriptome sequenced and treated with Sorafenib, Sunitinib, Axitinib, combined Sorafenib/Sunitinib, or alternating therapy of Sorafenib/ Sunitinib. e892 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 RESULTS: Sorafenib/Sunitinib monotherapy, combined or alternating treatment groups demonstrated more significant anti-tumor activity, as compared to Axitinib monotherapy (P<0.05). Most interestingly, the PDX of KI2368, in contrast to KI2367, demonstrated significant anti-tumor activity to Sunitinib monotherapy, Sorafenib and Sunitinib combination and alternating treatment groups, but not to Sorafenib or Axitinib monotherapy (P<0.05). A total of 1725 genes have > 5-fold higher expression levels in KI2367 than in KI2368, including the relevant drug targets: PDGFA, PDGFB and PDGFRA. A total of 994 genes have > 5-fold higher expression in KI2368 than in KI2367. Against human reference genome, 5539 and 5827 protein change variants were respectively found in KI2367 and KI2368, 4023 common variants in both samples. We also found 20 and 4 in-frame gene fusions in KI2367 and KI2368, but no common in-frame fusion was detected.
CONCLUSIONS: These results suggest the presence of the intra-tumor molecular heterogeneity in this patient, which could influence the clinical outcome of targeted therapies. Multiple biopsy and genomic analysis of intra-tumor molecular heterogeneity could potentially help guide more effective plan in selecting targeted therapies for ccRCC patients. METHODS: To answer these questions, we used immunofluorescence to characterize WT samples and identified CITED1þ, SIX2þ and CITED1SIX2þ cells within WT samples and compared our findings with NP isolated from human fetal renal samples. In addition, using our established Smartflare isolation methods, we obtained live CITED1SIX2 positive cells from WT samples, isolated RNA and performed RNA-Seq.
RESULTS: We confirm the expression of CITED1 and SIX2 positive cells within the WT samples, and for the first time we also established the existence of a side population expressing both CITED1 and SIX2, as observed in the true NP within the human fetal kidney at week gestation 16. Further characterization of the WT also identified the absence of mature renal cell markers such as Nephrin and Aquaporin along with the absence of renal developmental markers such as Calbindin and LEF1. However, unlike NP from fetal kidney, some WT cells express NPHS2 and WT1 similarly to developing structure such as the renal vesicle, C-shaped bodies, S-shaped bodies, and glomeruli. Using Smartflare technology we have identified on average 6.7% SIX2þ, 0.1% CITED1þ, and 12.43% CITED1SIX2þ cells, while human fetal samples express .16% of CITED1SIX2þ, 19.8% of SIX2þ and hardly any CITED1þ cells. Our RNA-Seq analysis identified different pathways expressed between NP isolated from fetal kidney and WT, specifically in relation to their cell cycle and cell cycle regulators.
CONCLUSIONS: This work suggests that we can identify and select for the first time CITED1SIX2 cell present within the WT. RNASeq data showed the presence of mechanisms essential for tumor formation. The discovery of this mechanism can help the development of new strategies aimed at halting tumor progression.
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INTRODUCTION AND OBJECTIVES: von-Hippel Lindau (VHL) disease is an autosomal dominant inherited disorder in which affected individuals develop cystic and solid growth in multiple organs. While VHL is caused by germline alterations of the VHL gene, the manner of allelic loss is variable. Previous work has shown there may be genotype-phenotype effects in VHL, wherein the manner of alteration of VHL affects the phenotypic manifestations of the disease. We sought to characterize the genotype-phenotype alterations seen in a large cohort of patients treated at our institution.
METHODS: A prospective registry of patients with VHL treated at the National Cancer Institute was queried for germline mutation type and phenotypic manifestations. Germline mutations were categorized into missense, partial deletion, nonsense, frameshift, complete deletion, splice site alteration, amino acid insertion/deletion, or silent. The following manifestations were assessed: central nervous system (CNS) hemangioblastomas, retinal angiomas, endolymphatic sac tumor, solid kidney tumors, kidney cysts, pheochromocytoma, solid pancreatic tumors, pancreatic cysts, and epididymal cyst adenomas. Patients were excluded if neither their personal nor family genotype were known.
RESULTS: A total of 766 patients with genotype and phenotype information representing 402 VHL families were available for analysis. Table 1 demonstrates phenotypic associations by germline mutation type. The most common manifestation was CNS hemangioblastomas, with 78.9% of individuals found to be affected. Solid kidney tumors were seen in 57.3% of patients. Patients with complete deletions were at lower risk for development of several manifestations relative to the rest of the cohort, including solid kidney tumors, retinal angiomas, endolymphatic sac tumors and pheochromocytomas. Patients with missense mutations have an increased frequency of pheochromocytomas but reduced occurrence of renal tumors when compared to patients with other mutation types.
CONCLUSIONS: These data indicate that there is a genotypephenotype effect in VHL. These findings have potential implications for screening and may provide insight into disease biology.
